Results 71 to 80 of about 23,157 (220)
Effect of pregnancy on emtricitabine pharmacokinetics [PDF]
HIV Medicine, 2011 ObjectivesThe aim of the study was to describe emtricitabine pharmacokinetics during pregnancy and postpartum.MethodsThe International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT), formerly Pediatric AIDS Clinical Trials Group (PACTG), study P1026s is a prospective pharmacokinetic study of HIV‐infected pregnant women taking ...
A M, Stek +12 more
openaire +2 more sources
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain [PDF]
Farmacia Hospitalaria, 2017 Objective: Fixed-dose combinations of antiretroviral drugs have meant an important step forward in simplifying treatment and improving compliance and has led to an increased effectiveness of therapy, a viral load decrease and improving the quality of ...
Santiago Moreno Guillen +7 more
doaj +1 more source
Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley +1 more source
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. [PDF]
PLoS ONE, 2012 Changes in endothelial function, measured as flow-mediated dilation (FMD) of the brachial artery, has not been systematically assessed beyond 6 months of initiation of antiretroviral therapy (ART) when drug-related effects might offset initial ...
Samir K Gupta +5 more
doaj +1 more source
Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.Abstract Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice‐yearly lenacapavir, epidemiological projections are needed to understand the ...
Mia Moore +11 more
wiley +1 more source
AIDS Research and Treatment, 2012 We investigated the effect of food on the steady-state pharmacokinetics of a proprietary fixed-dose combination (FDC) tablet containing tenofovir disoproxil fumarate (TDF)/emtricitabine/efavirenz.
Mohammed Lamorde +11 more
doaj +1 more source
Journal of Medical Virology, Volume 98, Issue 8, August 2026.ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca +18 more
wiley +1 more source
The Lancet HIV, 2019 BACKGROUND Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of HIV-1-infection and might be better tolerated than other integrase inhibitor-based single-tablet regimens, but ...
D. Wohl +13 more
semanticscholar +1 more source
PLoS ONE, 2013 IntroductionLamivudine and emtricitabine are considered equivalent by several guidelines, but evidence of comparable efficacy is conflicting.MethodsWe searched two databases up to June 30 2013 to identify randomized and quasi-randomized trials in which ...
Nathan Ford +6 more
doaj +1 more source
AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus
BMC Research Notes, 2011 Background Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS.
Semvua Hadija H, Kibiki Gibson S
doaj +1 more source